Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: A new biomarker for predicting unstable plaque

European Journal of Vascular and Endovascular Surgery

Volumn 43, Issue 2, 2012, Pages 154-159

  Sarlon Bartoli, G ^a   Boudes, A ^a   Buffat, C ^b   Bartoli, M A ^a   Piercecchi Marti, M D ^c   Sarlon, E ^d   Arnaud, L ^a   Bennis, Y ^a   Thevenin, B ^c   Squarcioni, C ^c   Nicoli, F ^c   Dignat George, F ^a   Sabatier, F ^a   Magnan, P E ^c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c TIMONE HOSPITAL   (France)

^d INSERM   (France)

Author keywords

Atherosclerosis; High grade carotid stenosis; Lp PLA2; Unstable plaque

Indexed keywords

ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHOSPHOLIPASE A2; STATIN;

AGED; ARTICLE; ASYMPTOMATIC DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID STENOSIS; CROSS-SECTIONAL STUDIES; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES;

EID: 84855558226     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2011.10.009     Document Type: Article

References (19)

1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade stenosis. NEJM 1991;325:445-53.
2. Naylor AR, Gaines PA, Rothwell PM. Who benefits most from intervention for asymptomatic carotid stenosis: patients or professionals? Eur J Vasc Endovasc Surg 2009;37:625-32.
3. Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, et al Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010;376:1074-84.
4. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity Creactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg 2003;38:1018-24. (Pubitemid 37409637)
5. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al, for the Lp-PLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44.
6. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-31. (Pubitemid 40627835)
7. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101:51F-7F.
8. Mannheim D, Herrmann J, Versari D, Gössl M, Meyer FB, McConnell JP, et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008;39:1448-55.
9. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-9. (Pubitemid 30336554)
10. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull Jr W, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 1995;92:1355-74.
11. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas heart study. Atherosclerosis 2008;199:110-5. (Pubitemid 351842698)
12. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: west of Scotland coronary prevention study group. N Engl J Med 2000;343:1148-55.
13. Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the atherosclerosis risk in communities (ARIC) study. Stroke 2009;40:376-81.
14. Caslake MJ, Packard CJ, Robertson M, Cooney J, Nelson JJ, Ford I, et al. Lipoprotein- associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the prospective study of pravastatin in the elderly at risk (PROSPER). Atherosclerosis 2010;210:28-34.
15. Madjid M, Ali M, Willerson JT. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Tex Heart Inst J 2010;37:25-39.
16. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010;122:2183-200.
17. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006;166:2073-80. (Pubitemid 44631394)
18. Wolfert RL, Kim NW, Selby RG, Sarno MJ, Warnick RG, Sudhir K. Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel marker of cardiovascular risk. Circulation 2004;110:309.
19. Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, et al. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 1995;118:173-81. (Pubitemid 26011482)